http://michelex.com
Michelex Corporation Contact Information:
Michelex Corporation
5 County Route 42
Massena, NY 13662-1569
Phone 207-406-2588
Fax 732-845-3286
Investor_Relations@michelex.com
Dino A. Sawyer
207-406-2588
If you would like to be receive email notification of Michelex news, PR releases, SEC filings, etc., please send me an email requesting that you be included on the 'Michelex Mailing List'.
Management:
Frank T. LaSusa, President, CEO and Director
Since 2009, he has been the President of J.C. Marketing, a pharmaceutical consulting company. From 2007 until 2009, Mr. LaSusa was the Vice President of Trade and National Accounts for Auriga Pharmaceuticals. Mr. LaSusa has 30 years experience as an executive in the Pharmaceutical Industry. Mr. LaSusa holds a B.S. in Biology from Marquette University and a Pharmacy degree from the University of Wisconsin.
VCGBIO - Implementation Team
Frank T. LaSusa, R.Ph. - VP of Trade & Commercialization
"During his 30 year career in the pharmaceutical industry, Mr. LaSusa has held various positions ranging from sales representative to Executive VP Sales and Marketing. In the last 25 plus years he has been responsible for Trade Sales/National Accounts for Brand, Generic and OTC products including injectables, liquids and solid dosage pharmaceutical products. Customer responsibilities included pharmaceutical distributors, wholesalers, chain drug and mass merchandise retailers, independent pharmacy, managed care and GPO accounts. Mr. LaSusa was also responsible for new product launch planning and stocking throughout the distribution network and implementing pull-through programs to help facilitate sales growth.
Product categories Mr. LaSusa has worked with include pain management, cough cold, respiratory and infection control. The companies Mr. LaSusa held positions at included Auriga Labs, PAI, ENDO, Prefil, SoloPak and Bristol-Myers Squibb. He also acted as the key company representative at all national association meetings and trade shows.
Mr. LaSusa is a graduate of Marquette University with a Bachelor of Science Degree in Biology. He is also a graduate of The University of Wisconsin, School of Pharmacy and is a licensed Pharmacist".
http://www.vcgbio.com/index.php?option=com_content&view=article&id=40&Itemid=33
Dino A. Sawyer, Secretary/Director
Mr. Sawyer, age 52, is a shareholder in the Company and will serve without compensation until such time as the Board deems appropriate. Mr. Sawyer has advanced approximately $3,500 in expense costs to the Company in the last year, and has had no other transactions with the Company. Mr. Sawyer is retired. Mr. Sawyer is an experienced investor in "micro-cap" companies, and is an advocate for corporate transparency. Previously, he was the Director of Human Resources and Administrator of Sales & Marketing for the Dartmouth Printing Company, where he managed the training of over 250 employees in Statistical Process Control techniques and assisted in implementing a 'Consultative Sales' approach that was employed by the national sales force. Mr. Sawyer holds a B.S. in Economics from the University of New Mexico.
Venkat Kakani, Treasurer
CEO - Pristine Pharma Corporation
Mr. Kakani, CEO of Pristine Pharma Corp., has been a part of the pharmaceutical industry for over 18 years. In 1991, he earned an M.B.A. from Rutgers University, Graduate School of Management, with major in Finance and International Trade. Prior to that, he earned an M.S. (Ag) in Genetics (1985) and a B.S. (Ag) (1982) from Andhra Pradesh Agricultural University in India.
Mr. Kakani, as a founder and executive of Medico and its subsidiary AUM, has demonstrated his strong background and experience as an entrepreneur and manager, while building Medico both domestically and internationally. Since Medicos founding in 2001, Mr. Kakani has utilized his leadership skills, multi-tasking abilities, and operating skills to build the business. Prior thereto, while working at E-Z Weld International, Inc., from 1991 to 2001 and American Standard Products from 1994 until 2001, Mr. Kakani acquired extensive knowledge of business processes and applications, job costing methods and operating techniques that he has successfully applied to Medicos business model during the manufacturing scale-up. Mr. Kakani has established strong relationships with importers, exporters and distributors around the world and is comfortable working within international banking, trade laws and practices. Prior thereto, from 1985 to 1987 Mr. Kakani worked for Syndicate Bank in India as a Lending Officer. Mr. Kakani received his B.S (Ag) degree in 1982 and his M.S (Ag) degree in Genetics in 1985 from Andhra Pradesh Agrl University, India. In 1991, he received his M.B.A. degree from Rutgers University Graduate School of Business School, with major in Finance and International Trade.
FORM 8-K February 9, 2012 Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On February 4 2012, pursuant to a written consent in lieu of a special meeting of the shareholders of Michelex Corporation (the Company), which consent was received by the Company on January 19, 2012, Sabir Saleem, Midhat Syed and Albert Lacle were removed as directors of the Company. Mr. Saleem was, until his removal on February 4, 2012, the Chairman of the Board of Directors of the Company.
On February 4, 2012, by action of the remaining member of the Board of Directors of the Company, Dino A. Sawyer was appointed as a Director of the Company to serve until the next annual meeting of shareholders. Mr. Sawyer, age 52, is a shareholder in the Company and will serve without compensation until such time as the Board deems appropriate. Mr. Sawyer has advanced approximately $3,500 in expense costs to the Company in the last year, and has had no other transactions with the Company. Mr. Sawyer is retired. Mr. Sawyer is an experienced investor in "micro-cap" companies, and is an advocate for corporate transparency. Previously, he was the Director of Human Resources and Administrator of Sales & Marketing for the Dartmouth Printing Company, where he managed the training of over 250 employees in Statistical Process Control techniques and assisted in implementing a 'Consultative Sales' approach that was employed by the national sales force. Mr. Sawyer holds a B.S. in Economics from the University of New Mexico.
On February 4, 2012, by action of the remaining member of the Board of Directors of the Company, Frank T. LaSusa, RPh was appointed as a Director of the Company to serve until the next annual meeting of shareholders. Mr. Lasusa, age, 58, will serve without compensation until such time as the Board deems appropriate. Since 2009, he has been the President of J.C. Marketing, a pharmaceutical consulting company. From 2007 until 2009, Mr. LaSusa was the Vice President of Trade and National Accounts for Auriga Pharmaceuticals. Mr. LaSusa has 30 years experience as an executive in the Pharmaceutical Industry. Mr. LaSusa holds a B.S. in Biology from Marquette University and a Pharmacy degree from the University of Wisconsin.
On February 4, 2012, by unanimous consent of the Board of Directors, Sabir Saleem (Chairman and CEO), Midhat Syed (Secretary) and Albert Lacle (President) were removed as officers of the Company. Negotiations regarding severance are ongoing as of the date hereof.
On February 4, 2012, by unanimous consent of the Board of Directors, with Mr. LaSusa abstaining, Frank T. LaSusa was appointed President and CEO of the Company. Mr. LaSusa will serve without compensation until such time as the Board deems appropriate. The Board will convene a Compensation Committee which will address Mr. LaSusa's compensation.
On February 4, 2012, by unanimous consent of the Board of Directors, with Mr. Kakani abstaining, Venkat Kakani was appointed Treasurer of the Company. Mr. Kakani will serve without compensation until such time as the Board deems appropriate. The Board will convene a Compensation Committee which will address Mr. Kakani's compensation.
On February 4 2012, by unanimous consent of the Board of Directors, with Mr. Sawyer abstaining, Dino A. Sawyer was appointed Secretary of the Company. Mr. Sawyer will serve without compensation until such time as the Board deems appropriate. The Board will convene a Compensation Committee which will address Mr. Sawyer's compensation.
Item 8.01. Other Events
As of February 4, 2012, the address of the Company's principal executive offices has been moved. The new address is:
Michelex Corporation
5 County Route 42
Massena, NY 13662
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized.
Michelex Corporation
/s/ Frank T. LaSusa
Frank T. LaSusa, President
June 01, 2011 09:27 ET Michelex Announces Signing of Contract Between Pristine Pharma Corporation and International Trade Association of America
NEW YORK, NY--(Marketwire - Jun 1, 2011) - Michelex Corporation (PINKSHEETS: MLXO) ("Michelex") announced today that its subsidiary, Pristine Pharma Corporation, has signed a contract with International Trade Association of America for export distribution of six over-the-counter pharmaceutical products. This contract is valued initially at $5.5 million per year, and delivery of these products is to begin in August 2011.
Michelex also announces commencement of due diligence for the acquisition of Vitacoat Corp., Alpro Inc., and G&P International LLC. Michelex expects to complete the due diligence process by the end of June.
In further news, Michelex has received, from the prior management of Michelex, long-awaited financials, dating to FY 2009, and said financials were forwarded for auditing. The current management of Michelex is finalizing accounts through December 2010 and expects the financial audit through FY 2010 to be completed by the end of June. 
Michelex Corporation:
Marketwire: http://tinyurl.com/75tz7n3
Yahoo: finance.yahoo.com/q
michelex.com/html/index.aspx
The
company website has news not issued as "Press Releases".
The following articles were
published by "Upstate" New York newspapers, not as "Press Releases".
SUNDAY, NOVEMBER 27, 2011 - Massena Waits For Pharma Company MASSENA - From his home in Wyoming, Iowa, Glenn E. Pauly is concerned about the future of a Massena pharmaceutical facility.
On an island off the coast of Maine, Dino A. Sawyer is wondering the same thing. And in Wallingford, Conn., a building supply company is continuing to await payment for doors installed at the facility.
They're all concerned about the future of Pristine Pharma, a company which one year ago this week announced plans to open a pharmaceutical plant in the former Michele Audio building on County Route 42. Pristine's plans were great news for Massena, which was continuing to reel from the closure of the General Motors plant in 2009.
The company's CEO, Venkat E. Kakani, originally said the plant on County Route 42 would start production with 25 employees by as early as late March and could employ 100 by the summer of 2012.
Crews worked through the winter to convert the former Michele Audio building into a pharmaceutical plant that would produce liquid medicine. By early March, Pristine hired its first seven employees here - two consultants, a chemist, a mechanical engineer, an operations staffer and two packaging employees - and reportedly produced a batch of DeWitt's Worm Syrup here to be shipped to Guyana, Haiti and Jamaica, Mr. Kakani said.
But soon after, activity at the plant fell quiet. Mr. Kakani had reported the seven initial employees had been moved to the company's New Jersey operations. By summer, Fred I. Wilson, credit manager at Kamco Supply Co. in Wallingford, Conn., was still looking for payment for doors installed the previous winter.
The entrance to the Massena building was locked, and for a time, phone numbers for both Massena and the company's New Jersey office were disconnected.
Four months later, Mr. Wilson said his company has still not received payment for the doors. Kamco has issued a mechanic's lien on the property.
"It's very confusing. I don't understand the whole thing," Mr. Wilson said. "The whole thing is strange."
As summer turned into fall and more time elapsed, investors grew more concerned too, according to Mr. Pauly and Mr. Sawyer. Both had invested in Pristine's parent company, Michelex, which had recently reorganized. The company was trading on "pink sheets," a type of penny stock outside of the New York Stock Exchange that is high risk, high reward, according to Mr. Sawyer, 52 a retiree living on Dingley Island, Maine.
"They're considered the wild west of investing," Mr. Sawyer said. "They typically don't come under Security and Exchange Commission) overview."
Pristine's plans appeared to hold promise and the company was primed to become the principal profit driver for the "new Michelex," Mr. Sawyer said, Michelex is currently trading for about two cents per share. Mr. Sawyer purchased 6 million shares; Mr. Pauly purchased 15 million.
As progress at Pristine's Massena facility came to a stand still, so did communication to investors, Mr. Sawyer said. The last press release Pristine issued on its Web site is from June 1. The company had issued a "draft final audit" of its finances over the summer, but did not specify whether the document was a draft, or the final audit.
Mr. Sawyer still sees promise and potential in Pristine. But he has grown increasingly frustrated with the lack of communication from management.
His last communication was in April. He has sent four or five additional emails since then which have received no response.
"The management has been dysfunctional. I think they've been derelict in some of their basic fiduciary responsibilities," Mr. Sawyer said. "They really have not done a very good job, to put it mildly, of making it look like the company was worth investing in."
Mr. Sawyer said he did not believe Pristine was a scam. And as a pink sheet stock, Michelex does not have to provide quarterly reports like companies on the NYSE.
But Michelex has not made any effort to make itself appear to be a legitimate investment and separate itself from other pink sheet stocks, Mr. Sawyer said.
"Even though they're not required, they can still send out quarterly and annual reports," he said. "If they were transparent, they would be sending a signal of 'We're not like these other companies.'"
"We want them to do the types of things that increase the probability of them being successful," Mr. Sawyer said.
Pristine is still planning on opening in Massena, according to Mr. Kakani. He is currently working on the details and said he hopes to have an update on the plant by December.
Pristine was founded in 2009 before a merger with Michelex, Mr. Kakani said. It had originally contracted work out to other pharmaceutical companies in New Jersey, and its Massena operations were to be its first owned and operated plant.
With the merger, Michelex had promised to fund Pristine's Massena startup, Mr. Kakani said. That funding has not yet come through.
"Michelex is not providing the finances. They were supposed to provide working capital finances. They did not," Mr. Kakani said. "Michelex had promised to provide working capital, which they haven't so far."
Until that happens, Mr. Kakani is reverting to his old business model of contracting work out to other New Jersey manufacturers. A Russian export company and Prstine customer, ITA of America, had toured the Massena facility last winter and is currently having its product produced under Pristine's New Jersey arrangement, Mr. Kakani said..
"Within my limited resources, I am trying to deliver product to the customers," he said.
He blamed the funding draught to Pristine on an internal struggle within Michelex. A final audit of company finances will be coming soon, he said. He said he answers questions and emails about Pistine promptly, but cannot answer questions about Michelex investments as they are out of his control, he said.
"I'm hoping we'll be able to resolve these issues within the next few weeks," he said.
Any news would be a positive step for Mr. Pauly, who echoed many of Mr. Sawyer's sentiments. Like Mr. Sawyer, he still sees much promise in Pristine's plan to ramp up operations in Massena.
"With multiple announcements regarding contracts to supply millions of dollars in product, I began investing more and more money into Michelex. It seemed like a fantastic ground-floor opportunity," he said in an email.
But the lack of communication from Pristine has hurt his confidence in the company.
"I question the commitment of upper management," according to Mr. Pauly, 40, who said he works in sales for a large pharmaceutical company. "It doesn't boost confidence when the phone lines are inoperable and upper management does not respond to emails."
"There are multiple shareholders like myself who would really like some answers to basic questions about the status of the business today and plans for taking it forward."
http://www.ogd.com/article/20111127/ADV01/311279980/-1/ogd01
MARCH 8, 2011 Pristine Pharma Starts Operations
By BRIAN HAYDEN
TUESDAY, MARCH 8, 2011
MASSENA - Pristine Pharma Corp. has begun its manufacturing operations here.
The company shipped out its first medicine on Feb. 23, according to Pristine CEO Venkat E. Kakani.
Pristine Pharma produced a batch of Dewitts Worm Syrup to be exported to customers in Guyana, Haiti and Jamaica. That shipment of de-worming medication came a week after the company registered with the Food and Drug Administration.
Seven employees currently work at the 32,000- square-foot plant on County Route 42: two consultants, a chemist, a mechanical engineer, an operations staffer and two packaging employees.
Three of those hires came from applications filed in the New York state Labor Department's Massena office, Mr. Kakani said. The company is still expecting to grow to 25 employees at the facility by the end of March.
The company's first medicine shipment came only months after New Jersey- based Pristine bought the former Michele Audio building from Massena businessman Thomas Gramuglia.
The Massena plant is the first manufacturing facility owned by Pristine, which had previously contracted its work out to other pharmaceutical manufacturers.
Massena's proximity to the Canadian market and the Port of Montreal were high selling points to locate the company in Massena, Mr. Kakani said previously.
"We are very happy," Mr. Kakani said. "We are very proud to bring that plant there in a short amount of time."
Pristine Pharma recently landed a $2 million contract with a U.S.-based Russian export company to produce aspirin for Russian customers. Aspirin will likely be produced in the plant in the next two to three months, Mr. Kakani said.
The company is also finalizing a contract to make nasal spray for Russian customers. If that contract comes through, nasal spray will be produced in the next four to five months.
A multi-million dollar contract is also being negotiated with a U.S- based nursing home medicine supplier, Mr. Kakani said.
"If they come through, the plant will be full very soon," Mr. Kakani said.
Pristine Pharma is still planning to grow to 100 employees in the next 18 months. Approximately 30 percent of those jobs would be chemists, pharmacists and skilled engineers. The rest of the jobs would be in assembly, packaging, warehousing and distribution.
http://www.mpcourier.com/article/20110308/DCO01/303089914/-1/dco
February 25, 2011 Michelex Announces First Shipment of Pharmaceutical Products From Massena Facility
Press Release Source: Michelex On Friday February 25, 2011, 9:45 am
NEW YORK, NY--(Marketwire - 02/25/11) - Michelex Corporation (Pinksheets:MLXO - News) ("Michelex") ... is pleased to announce the shipment of the first batch of products from Pristine Pharma Corporation's newly constructed manufacturing facility in Massena, NY, on Feb 23, 2011, to an export distributor for Caribbean countries.
Mr. Venkat Kakani, CEO of Pristine, is excited about near-term plans to expand Pristine's North American territory beyond the Caribbean by distributing, for the first time, its products to Central America.
In further news, the FDA's Center for Drug Evaluation and Research ("CDER-FDA") issued labeler code 76044 to Pristine on Feb 22, 2011. This labeler code is the prefix to the New Drug Code Number (NDC#) for each drug manufactured at Pristine's facility. NDC numbers appear on drug labels and packages identifying the manufacturer of the drug product.
February 17, 2011 Michelex (PINKSHEETS: MLXO) Announces Successful Registration of Pristine Pharma Corporation's Manufacturing Facility With the US FDA
Thursday February 17, 2011, 8:55 am EST
NEW YORK, NY--(Marketwire - 02/17/11) - Michelex Corporation (Pinksheets:MLXO - News) ("Michelex") ... is pleased to announce the successful registration of Pristine Pharma Corporation's ("Pristine") newly constructed manufacturing facility with the United States Food and Drug Administration ("FDA"). Having met cGMP (Current Good Manufacturing Practices) requirements, Pristine commenced operations and will deliver, for export, the first lot of its products in February.
The FDA registration information can be searched by name on the FDA website:
http://www.accessdata.fda.gov/scripts/cder/drls/default.cfm
During the third week of January 2011, Mr. Venkat Kakani, CEO of Pristine, provided a tour of the Massena, NY, facility to Mr. Maxim Pantchenko, President of the International Trade Association of America, an export distributor of OTC pharmaceuticals to Russia. ITA placed orders with Pristine for two products worth over $2.0 million, and a contract for four more products for near term fulfillment is under negotiation. During his visit to Pristine's facility, Mr. Pantchenko confirmed that ITA will source its liquid OTC pharmaceuticals exclusively from Pristine. Press coverage of Mr. Pantchenko's visit is available at the following:
http://www.mpcourier.com/article/20110122/DCO01/301229939
http://www.watertowndailytimes.com/article/20110122/NEWS05/301229954
http://www.wwnytv.com/news/local/Pharmaceutical-Company-Getting-Ready-To-Do-Business-In-Massena-114385734.html
Having successfully completed registration with the FDA, Pristine is currently fulfilling existing orders. As it does so, the company is working to expand its operations, its product portfolio, and its customer base.
MICHELEX
Michelex Corporation, founded in 1999, is currently comprised of subsidiaries with a diversified portfolio of businesses in the areas of financial services and pharmaceutical drug manufacturing and distribution.
PRISTINE
Pristine Pharma Corporation was founded in 2009 and became a wholly owned subsidiary of the Michelex Corp. in July 2010. Pristine owns pharmaceutical manufacturing assets worth $3.5 million for the production and packaging of both liquid and solid dose medicines. Pristine supplies National Brand Equivalents of Over The Counter medicines to national and international wholesalers and, to retailers in store brands, private-label, and its own brand, "NUMED."
Venkat Kakani
Mr. Kakani, CEO of Pristine Pharma Corp., has been a part of the pharmaceutical industry for over 18 years. In 1991, he earned an M.B.A. from Rutgers University, Graduate School of Management, with major in Finance and International Trade. Prior to that, he earned an M.S. (Ag) in Genetics (1985) and a B.S. (Ag) (1982) from Andhra Pradesh Agricultural University in India.
More information about Michelex Corp. and Pristine Pharma Corp. is available at the following:
http://www.michelex.com
http://www.pristinepharmacorp.com
Feb 24, 2011 FDA-CDER issued Labeler Code to Pristine Pharma Corporation
FDA's Center for Drug Evaluation and Research ("CDER-FDA") issued labeler code 76044 to Pristine Pharma Corporation on Feb 22, 2011. This labeler code is the prefix to the New Drug Code Number (NDC#) for each drug that is manufactured at Pristine's facility. NDC numbers appear on drug labels and packages identifying the manufacturer of the drug product.
January 23, 2011 Export Distributor Visited Massena Facility
"On January 20 & 21, 2011, the management of Pristine hosted a welcome to an export executive, whose firm has been exporting pharmaceuticals to Russia and CIS countries for over 10 years. The executive was given a detailed tour of Pristine's manufacturing facility in Massena, NY.
Upon completion of the tour, the export executive expressed his profound confidence in Pristine Pharma, in providing them with all of their liquid OTC medicine requirements. A contract is already in the works between the firms which reflects the confidence of the customer in Pristine's ability to meet their market demands.
The excerpts of the conversation with the TV and Print media on Jan 21, 2011 on this occasion can be found at the following web links."
http://www.wwnytv.com/news/local/Pharmaceutical-Company-Getting-Ready-To-Do-Business-In-Massena-114385734.html
http://www.watertowndailytimes.com/article/20110122/NEWS05/301229954
http://www.mpcourier.com/article/20110122/DCO01/301229939/-1/dco
JANUARY 22, 2011 Medicine maker set to open next month
MASSENA FACILITY: CEO says building's infrastructure allowed quick development of pharmaceutical plant
By BRIAN HAYDEN
JOHNSON NEWSPAPERS
SATURDAY, JANUARY 22, 2011
MASSENA - The CEO of Pristine Pharma Corp. expects the company to open its manufacturing facility here next month.
Venkat E. Kakani visited this week to meet with local economic development officials and tour the progress of the 32,000-square-foot facility on County Route 42.
Normally, a pharmaceutical plant takes more than a year to build and complete, Mr. Kakani said. But the infrastructure in the former Michele Audio building allowed the company to convert it into a pharmaceutical facility in just three months. The company still needs to move in more equipment and make additional installations in its production facility before it can open.
"This facility is very much in move-in condition," Mr. Kakani said.
Nearly 180 applications have poured in to the state Labor Department for the first 25 positions for which the company is hiring - chemists, mechanical engineers and assembly line workers.
Pristine Pharma originally planned to recruit talent from Central and Western New York, but the company is now planning to do nearly all of its hiring locally because of the large talent pool in the area, Mr. Kakani said.
"The resumes are very, very qualified resumes," he added.
The company will initially make generic over-the-counter nasal and throat sprays in the plant under store brand names and its own label, NuMed. It will then branch out to stomach remedies and cough and cold medicines as time goes on, Mr. Kakani said.
Pristine Pharma has plans to grow to 100 employees over the next 18 months. A company sign in front of the building now greets drivers as they head into the village.
Mr. Kakani said he also spoke Thursday night with Rep. William L. Owens, D-Plattsburgh, who offered his support as the company opened.
Pristine Pharma is planning to use its proximity to the Canadian border to tap into the market and will also ship its products to Russian markets using the Port of Montreal.
Mr. Kakani showed the facility on Friday to Maxim Pantchenko, president of ITA of America, a Florida-based exporting company.
Mr. Pantchenko said ITA is one of the leading U.S. exporters of aspirin to Russia. Now, his company is negotiating a contract with Pristine to export nasal sprays to Russia as well.
ITA already contracts with a manufacturing plant in Long Island. But shipping out of the Port of Montreal is less expensive than shipping out of New York City, he said.
Any new products ITA ships to Russia would first have to be approved by Russia's Ministry of Health, Mr. Pantchenko said. But he was optimistic the contract would eventually be approved.
MORE... http://www.watertowndailytimes.com/article/20110122/NEWS05/301229954
NOVEMBER 30, 2010 Medicine maker moves to Massena
Pristine Pharma Corporation is a relatively new company. It's made medicines in New Jersey and Middletown, New York for a year and a half. It sells them as store-brand labels in Walgreens, CVS, and Kinneys and exports them under the NuMed label to countries all over the world.
CEO Venkat Kakani says Massena came on his radar when Pristine Pharma became a subsidiary of Michelex Corporation, which once employed 200 people there. Kakani says he visited and fell in love.
When we travel from a busy metropolitan area in New York City and suburbs of New Jersey, the pureness of the water that is available in Massena, it's a nice place to be around.
Kakani says he sells a lot of medicines to Canada and to Russia and the Ukraine, so Massena made strategic sense.
The ports in Montreal are easy access for my customers so they save a lot of money.
Kakani says he plans to begin production at the old Michele Audio plant with a staff of 25 people. He says he expects 70 to 80 percent of those to be local hires.
Massena has been starving for new jobs. General Motors laid off hundreds of people when it shut down late last year. More than a hundred more people have been idled by an extended layoff at Alcoa.
Pristine Pharma CEO Venkat Kakani says he wants to expand and raise employment to 100 people, but he would need local and state help to do it. He's been talking with the St. Lawrence County Industrial Development Agency. IDA director Ray Fountain described the talks as "moving forward" but "preliminary".
Pristine Pharma also plans to apply for low cost power from the new St. Lawrence River Valley Redevelopment Agency. Kakani says he plans to submit the application soon.
For North Country Public Radio, I'm David Sommerstein.
http://www.northcountrypublicradio.org/news/story/16746/medicine-maker-moves-to-massena
November 29, 2010 WWNY-TV Pharmaceutical Company Looks To Locate In Massena
Story Published: Nov 29, 2010 at 5:00 PM EST
Story Updated: Nov 29, 2010 at 5:24 PM EST
Video of following text: www.wwnytv.com/news/local/Pharmaceutical-Company-Looks-To-Locate-In-Massena-110998044.html
If all goes as planned, a New Jersey-based pharmaceutical company could begin making over-the-counter drugs like cough syrup and other liquid medicines by January or February in Massena.
The company hopes to set up shop inside the old Michele Audio warehouse on Outer Willow Street - bringing new manufacturing jobs to the Massena area.
While workers spruce up the outside, equipment and other supplies are being stored inside as the early stages of the building's renovations get underway.
The Pristine Pharma Corporation's website says equipment has been moved to the 32,000 square foot facility where it will be installed to make private label brands and its own NuMed pharmaceutical products.
Company officials say numerous regulatory and financial approvals are needed before the Massena operation can begin production.
"We're happily leading towards Massena provided that we are welcome there with the proper incentives," said Albert Lacle, president and chief executive officer of Michelex Corporation, which owns Pristine Pharma.
Pristine Pharma hopes to export products to Canada and other markets.
The company's pharmaceutical products are currently contract manufactured at federally registered plants in New Jersey and New York and then distributed.
State incentives would be used to help finance the pharmaceutical plant.
The company is also hoping to secure an allocation of low-cost hydro power from the newly formed St. Lawrence River Valley Redevelopment Agency.
http://www.wwnytv.com/news/local/Pharmaceutical-Company-Looks-To-Locate-In-Massena-110998044.html
NOVEMBER 29, 2010 Maker of medicines coming to Massena
PRISTINE PHARMA CORP.: Company could employ about 100
By BRIAN HAYDEN
JOHNSON NEWSPAPERS
MONDAY, NOVEMBER 29, 2010
MASSENA - A New Jersey pharmaceutical company is planning to locate its manufacturing operations here.
Pristine Pharma Corp. expects to open its production facility in the former Michele Audio complex on County Route 42. The Prospect Park, N.J.-based company will produce cough syrup, pain reliever and other liquid medicines under store brand names and its own label, NuMed. The plant may employ up to 100 workers, according to Pristine CEO Venkat E. Kakani.
Approximately 30 percent of those jobs would be for chemists, pharmacists and skilled engineers, Mr. Kakani said. The rest of the jobs would be in assembly, packaging, warehousing and distribution.
"We would like to move there and set up operations and provide employment for the local community," Mr. Kakani said.
Most of the hires will be local, while some of the skilled workers may be recruited from Syracuse or Buffalo or other cities with a high concentration of medical employees, Mr. Kakani said.
Consultants retained by Pristine are in Massena preparing for the building's conversion. The opening of the plant is pending approval of state incentives and a power allocation believed to be coming from the St. Lawrence River Valley Redevelopment Agency. The facility may open as soon as February, Mr. Kakani said.
Pristine previously had contracted out its work to other manufacturing facilities in New Jersey, Mr. Kakani said. Owning its own facility will allow the business to take off, he said.
"We like the building," Mr. Kakani said. "It can be quickly converted into a pharmaceutical manufacturing facility."
Mr. Kakani said many of the medicines produced are for Canadian store brands, which made the Massena location ideal. The close proximity to the St. Lawrence Seaway also will allow the company to ship its goods more easily to large markets in Russia and the Ukraine.
Some of its domestic products can be found under store-brand labels at Kinney Drugs, Price Chopper, CVS, Rite Aid, Walgreens and Walmart, he said.
Pristine was founded in 2009 and became a subsidiary of the Michelex Corp. in July. Michelex once employed about 200 people in Massena between its audio division, where Pristine is moving, and its plastics division in Massena Industrial Park. Both of those plants have been phased out.
Michelex's retired CEO is Massena resident Thomas G. Gramuglia, who stepped down in May. Mr. Gramuglia's recommendation played a large role in Pristine coming to Massena, Mr. Kakani said. The company purchased the building from Mr. Gramuglia for $275,000 several weeks ago.
MORE... http://www.watertowndailytimes.com/article/20101129/NEWS05/311299971
NOVEMBER 27, 2010 Pharmaceutical Firm Plans Massena Facility MASSENA - A New Jersey-based pharmaceutical company is planning to locate its manufacturing operations here.
Pristine Pharma Corp. expects to open its production facility in the former Michele Audio complex on County Route 42. The Prospect Park, N.J.-based company will produce cough syrup, pain reliever and other liquid medicines under store brand names and its own label, NuMed. The plant may employ up to 100 jobs, according to Pristine Chief Executive Officer Venkat E. Kakani.
Approximately 30 percent of those jobs would be chemists, pharmacists and skilled engineers, Mr. Kakani said. The rest of the jobs would be in assembly, packaging, warehousing and distribution.
"We would like to move there and set up operations and provide employment for the local community," Mr. Kakani said.
Most of the hires will be local, while some of the skilled workers may be recruited from Syracuse, Buffalo and other cities with a high concentration of medical employees, Mr. Kakani said.
Consultants retained by Pristine are currently in Massena preparing for the building's conversion. The opening of the plant is pending approval of state incentives and a power allocation believed to be coming from the St. Lawrence River Valley Redevelopment Agency. The facility may open as soon as February, Mr. Kakani said.
Before now, Pristine had contracted out its work to other manufacturing facilities in New Jersey, Mr. Kakani said. Owning its own facility will allow the business to take off, he said.
"We like the building," Mr. Kakani said. "It can be quickly converted into a pharmaceutical manufacturing facility."
Mr. Kakani said many of the medicines produced are for Canadian store brands, which made locating in Massena ideal. The close proximity to the St. Lawrence Seaway will also allow the company to ship its goods more easily to its large markets in Russia and the Ukraine.
Some of its domestic products can be found under store-brand labels at Kinney Drugs, Price Chopper, CVS, Rite-Aid, Walgreens and Walmart, he said.
Pristine was founded in 2009 and became a subsidiary of the Michelex Corp. in July. Michelex once employed around 200 employees in Massena between its audio division, where Pristine is now locating, and its plastics division in the Massena Industrial Park. Both of those plants have since been phased out.
Michelex's retired CEO is Massena resident Thomas Gramuglia, who stepped down in May of this year. Mr. Gramuglia's recommendation played a large role in coming to Massena, Mr. Kakani said. The company purchased the building from Mr. Gramuglia under the limited liability company TI-Blatta LLC for $275,000 several weeks ago.
MORE... http://www.mpcourier.com/article/20101127/DCO01/311279902/-1/dco 
Michelex Share Structure: December 29, 2011
Authorized Shares: 1 Billion
Outstanding Shares: 1 Billion
Treasury Shares: 0
Restricted Shares: 365,572,645
Preferred Shares: 0 (none authorized or issued)
Source: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=70364509
May 14, 2012
Approximate number of holders of record as of the certification or notice date: 719
http://secfilings.com/searchresultswide.aspx?link=2&filingid=8612908
Transfer Agent; Colonial Stock Transfer Company, Inc.
Salt Lake City, UT 84111
(801) 355-5740 (MST)
www.colonialstock.com/
MLXO SEC Filings:
otcmarkets.com: www.otcmarkets.com/stock/MLXO/financials
SEC.gov: tinyurl.com/2bfotfq
Venkat Kakani 
August 19, 2010 - Michelex Press Release Excerpts: "In further news, Michelex through United has also acquired all of the issued and outstanding shares of Pristine Pharma Corporation ("Pristine"), a start-up Pharmaceutical manufacturing enterprise located in Central New Jersey. As a result of the acquisition, Pristine became a subsidiary of Michelex".
"Pristine sells Over The Counter pharmaceutical products in store brand, private label and its own control label, 'NUMED.' United has invested $1 million of working capital into Pristine, while another $3.5 million funding in the form of a convertible note was provided by a boutique hedge fund based in New York for the acquisition of manufacturing assets -- equipment, formulations and inventory".
finance.yahoo.com/news/Michelex-PK-MLXO-Acquires-iw-4045335977.html
[Jul 30, 2010] MICHELEX ACQUIRED PHARMACEUTICAL COMPANY
MICHELEX HAS ACQUIRED 100% OF THE OUTSTANDING SHARES OF PRISTINE PHARMA CORPORATION, A PHARMACEUTICAL MANUFACTURING AND DISTRIBUTION COMPANY THAT SELLS BOTH PRIVATE LABEL AND ITS OWN NUMED BRAND LABEL PHARMACEUTICALS. THE MANAGEMENT OF PRISTINE PHARMA IS VERY WELL EXPERIENCED IN EXPORT OF PHARMACEUTICAL DRUGS FROM USA AND ARE WELL REGARDED BY BOTH US DEPARTMENT OF COMMERCE AND NJ ECONOMIC DEVELOPMENT AUTHORITY FOR THEIR EXPERTISE IN EXPORTING US MADE PRODUCTS.
MANUFACTURING FACILITY: 5 COUNTY ROUTE 42, MASSENA, NY
Pristine Pharma Corp. "NUMED Brand" Name for National Brand Equivalents:
www.pristinepharmacorp.com/UploadedFiles/PRISTINE%20PHARMA%20PRODUCT%20LIST.pdf
viewer.zoho.com/docs/qdhtda
Pristine Pharma Corp. Product List, "National Brand Equivalents":
PRODUCTION SCHEDULES FOR PRISTINE PHARMA CORP. AT MASSENA, NY NEW FACILITY
11/23/10
"Non-Numed brand" products can be manufactured in Massena, NY without FDA registration of the facility.
"NUMED brand" products can only be produced after the new facility is registered with the FDA.
plma.com/
Pristine Pharma Corporation
Private Label Manufacturer's Association Trade Show
November 14th to 16th 2010, Rosemont Convention Center in Chicago.
Pristine Pharma Corp. - Domestic Clients (Pharmacies and SuperMarkets):
Pristine Pharma Corp. products are exported to: Canada, Russia, Ukraine, and Caribbean countries.
Source: Michelex newspaper and press releases.
February 24, 2011 - FDA's Center for Drug Evaluation and Research ("CDER-FDA") issued labeler code 76044 to Pristine Pharma Corporation on Feb 22, 2011. This labeler code is the prefix to the New Drug Code Number (NDC#) for each drug that is manufactured at Pristine's facility. NDC numbers appear on drug labels and packages identifying the manufacturer of the drug product.
| Firm Name | Facility
Establishment
Identifier | Data Universal
Numbering System Number | Address | Current
Registration
Year |
| PRISTINE PHARMA CORPORATION | | 964348853 | 5 COUNTY ROUTE 42, MASSENA, NY 13662, USA | 2011 |
www.accessdata.fda.gov/scripts/cder/drls/default.cfm
November 27, 2010 quote by Pristine Pharma Corp. CEO Venkat Kakani: "Mr. Kakani said many of the medicines produced are for Canadian store brands, which made locating in Massena ideal."
Massena, NY is located in upstate NY, marked as the Red "A" on the following map.
Massena is east of Ogdensburg, NY: "Ogdensburg, New York has a unique advantage. Situated on the Northern New York State Border with Canada, the Ogdensburg-Prescott International Bridge provides easy access to major market areas in New York, the Northeast and Canada. Seven of the top ten U.S. markets and 75% of Canada's population is located within close proximity of Ogdensburg. Transportation access via rail, water, highway, and air makes Ogdensburg a strategic location for both U.S. and Canadian markets".
Driving distances from Ogdensburg are:
Ottawa - 60 miles (91 kilometers)
Syracuse - 130 miles (209 kilometers)
Montreal - 130 miles (209 kilometers)
Toronto - 247 miles (398 kilometers)
New York City- 370 miles (595 kilometers)
www.ogdensport.com/about.html
Ogdensburg-Prescott International Bridge - Vehicular Transportation
between the USA and Canada
November 27, 2010 quote by Pristine Pharma Corp. CEO Venkat Kakani: "The close proximity to the St. Lawrence Seaway will also allow the company to ship its goods more easily to its large markets in Russia and the Ukraine".
"the seaway
The Great Lakes St. Lawrence Seaway System is a deep draft waterway extending 3,700 km (2,340 miles) from the Atlantic Ocean to the head of the Great Lakes, in the heart of North America. The St. Lawrence Seaway portion of the System extends from Montreal to mid-Lake Erie. Ranked as one of the outstanding engineering feats of the twentieth century, the St. Lawrence Seaway includes 13 Canadian and 2 U.S. locks".
Lock Systems
- Montreal to Lake Ontario - 2 U.S., 5 Canadian
- Welland Canal - 8 Canadian
- St. Mary's River - 4 U.S. parallel locks one transit (Army Corps of Engineers)
The Seaway Canals
The Seaway system is connected by 6 short canals with a total length of less than 60 nautical miles. There are 19 locks, filled and emptied by gravity.
- South Shore Canal: (two locks - St. Lambert and Ste. Catherine) 14 nautical miles from the Port of Montreal to Lake St. Louis
-
- Beauharnois Canal: (two locks) 11.3 nautical miles; links Lake St. Louis to Lake St. Francis
-
- Wiley-Dondero Canal: (two U.S. locks - Snell and Eisenhower) 8 nautical miles; provides access to Lake St. Lawrence
-
- Iroquois Canal: (one lock and a water level control facility) 0.3 nautical miles
-
- Welland Canal: (eight locks) Of the seven located at north end, three are twinned and contiguous; the eighth, at the south end, is a control lock 23.5 nautical miles; links Lake Ontario to Lake Erie
-
- St. Mary's Falls Canal: (four parallel locks of various dimensions at Sault Ste. Marie) links Lake Huron to Lake Superior
St. Lawrence Co. (NYS):
St. Lawrence Co. IDA 2011 Meeting Information: www.slcida.com/about-the-slc-ida/meeting-minutes-resolutions/2011-meeting-information.html
St. Lawrence Co. IDA News: www.slcida.com/ida-news.html
St. Lawrence Co. Government - Real Property: www.co.st-lawrence.ny.us/Departments/RealProperty/
"North Country" Media:
Daily Courier-Observer (Massena): www.mpcourier.com/
Watertown Daily Times: www.watertowndailytimes.com/
WWNY TV: www.wwnytv.com/
North Country Public Radio: www.northcountrypublicradio.org/index.html
New York State:
NYS Dept. of Labor - Expansion: www.labor.state.ny.us/stats/nor/norec.shtm
NYS Empire State Development: www.empire.state.ny.us/
North Country Regional Office: www.empire.state.ny.us/NorthCountry.html
Division of Small Business: www.esd.ny.gov/SmallBusiness.html
Secretaries of State, Corporate Information:
Connecticut: Commercial Recording Division (United Mortgage Bankers): www.concord-sots.ct.gov/CONCORD/online
New Jersey: Corporate and Business Information Reporting (Pristine Pharma Corp.): accessnet.state.nj.us/home.asp
New York: NYS Department of State, Division of Corporations (Pristine Pharma Corp.): tinyurl.com/4nxzktu
Utah: Division of Corporations (Michelex): secure.utah.gov/bes/action/details
U.S. Food and Drug Adminstration:
National Drug Code Directory (Type in the 5 digit Labeler Code): www.accessdata.fda.gov/scripts/cder/ndc/queryndclbl.cfm
National Drug Code Directory: www.accessdata.fda.gov/scripts/cder/ndc/default.cfm
Drug Firm Annual Registration Status: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/DrugRegistrationandListing/ucm070998.htm
U.S. National Institutes of Health:
DailyMed.com: dailymed.nlm.nih.gov/dailymed/about.cfm
Medline Plus: www.nlm.nih.gov/medlineplus/medicines.html
National Library of Medicine Gateway: gateway.nlm.nih.gov/gw/Cmd
Miscellaneous:
Drugs.com: www.drugs.com/
Drugsdepot.com: www.drugsdepot.com/catalog.php
RxList: www.rxlist.com/script/main/hp.asp
www.rallymonkey.com/video/kenindex.swf
http://stockcharts.com/h-sc/ui?s=MLXO&p=D&yr=0&mn=6&dy=0&id=p67055524657
Market Maker Signals on Level ll
100 - I need shares.
200 - I need shares badly,but do not take the stock down.
300 - Take the price down so I can load shares
400 - Keep trading it sideways.
500 - Gap the stock. This gap can be either up or down, depending on the direction of the 500 signal.
505 - Short on Shares
911 - Pending News
Market Makers Scams
Many market makers and organized clubs also get paid to manipulate stocks. In the case of a Market Maker, if they get a client who pays them to accumulate a particular stock at a certain price then the Market Maker will work either alone or in concert with other Market Makers to bring down the price of a stock in order for them to be able to accumulate the stock for their client. The only way to stop such devious practices is for individual investors to hold on to their stock if they have it and to support the stock by submitting their stocks as hot picks on here and for other investors to support the hot pick with their sentiments and/or recommendations. One would think that the SEC would put a stop to these Market Makers' practices but you see, the SEC is a mafia style organization whose top brass is in bed with the big players. For example, "shorting" a stock is equal to "defamation of character" and such practices must not be allowed at all. When you see an order for 300 shares, 600 shares or 900 shares know this: those are market maker signals to one another to manipulate the stock.
300 means bring the price down at least 30% and
600 means provide resistance and
900 means let the stock float.
You will usually see these trades early in the day, many times pre-market and when the volume slows down or around 1:30 - 2:30 PM EST
Whenever I see Canacrap, First, Annon and other brokerages (even Sprott 17% owner!) manipulating the SP with smal orders 100, 300, 400, 200... I know we are just before a pop in share price. The big boys are just trying to shake out the remaining weak hands.
Watching the trades go through you may sometimes notice very small executions. Some people believe, and remember this is just a theory, those small numbers could be the market maker signals to each other...
100 I need shares.
200 I need shares badly, but do not take the stock down.
300 Take the price down so I can load shares
400 Keep trading it sideways.
500 Gap the stock. This gap can be either up or down, depending on the direction of the 500 signal.
MLXO Board Policy:
Zero Tolerance for Spam, Bashing, Personal Attacks, or Distortions of Facts.
Disclaimer:
Information above is gathered from either the internet or from other sources that could prove to be unreliable. Please do you own Due Diligence as some information may be out of date. IHub and the Moderators of this board (MLXO) will not claim nor hold any responsibility for a person(s) financial decisions. If any in-valid information is located on the MLXO board, please notify one of the moderators immediately so corrections can be made.
Sign up for MLXO Email List here:
http://investorshub.advfn.com/boards/chairmail_sub.asp?board_id=3403
Sign up if you would like to receive "occasional" correspondence regarding Michelex and it's subsidiaries. The list is not intended to promote other stocks.